Cardiff Oncology, Inc. (CRDF)
1 Item 5.02 filing since 2026-10-27 · 1 with an open seat · roles: CMO. Nasdaq. Biological Products, (No Diagnostic Substances). State: CA.
| Score | Filed | Event | Role | Person | Seat | Summary |
|---|---|---|---|---|---|---|
| 70 | 2026-10-27 | Appointment | CMO | subscribers | Open | Cardiff Oncology, Inc. (CRDF): CMO Dr. Leila Alland appointed interim |
Executive changes at other companies: all filings · CEO · CFO · How Item 5.02 works